Publications (60)

2023

  1. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    The Lancet, Vol. 401, Núm. 10388, pp. 1584-1594

2022

  1. Obesity, chronic kidney disease progression and the role of the adipokine C1q/TNF related protein-3

    Nefrologia

2021

  1. Use of renin–angiotensin–aldosterone system blockade in controversial chronic kidney disease populations

    Medicina Clinica, Vol. 156, Núm. 11, pp. 561-567

  2. Renal long-term outcome of critically ill COVID-19 patients with acute kidney failure and continuous renal replacement therapy

    Clinical Kidney Journal

  3. A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?

    Kidney International

  4. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

    Kidney International, Vol. 99, Núm. 4, pp. 986-998

  5. Riesgo relacionado con la obesidad para la progresión de insuficiencia renal crónica y enfermedad cardiovascular tras emparejamiento por puntaje de propensión

    Hipertensión y riesgo vascular, Vol. 38, Núm. 2, pp. 63-71

  6. Obesity related risk for chronic kidney disease progression and cardiovascular disease after propensity score matching

    Hipertension y Riesgo Vascular, Vol. 38, Núm. 2, pp. 63-71

2020

  1. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain

    Kidney International

  2. The effect of renin–angiotensin–aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design

    Hipertensión y riesgo vascular, Vol. 37, Núm. 3, pp. 101-107

  3. Progresión de la enfermedad renal crónica en pacientes con hipertensión resistente sometidos a 2 estrategias terapéuticas: intensificación con diuréticos de asa vs. antagonistas de la aldosterona

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 40, Núm. 1, pp. 65-73

  4. Chronic kidney disease progression in patients with resistant hypertension subject to 2 therapeutic strategies: Intensification with loop diuretics vs aldosterone antagonists

    Nefrologia, Vol. 40, Núm. 1, pp. 66-74

2019

  1. Removal capacity of different high-flux dialyzers during postdilution online hemodiafiltration

    Hemodialysis International, Vol. 23, Núm. 1, pp. 50-57

  2. Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial

    Journal of Nephrology, Vol. 32, Núm. 4, pp. 581-587

  3. Obesity and chronic kidney disease progression-the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1

    Clinical Kidney Journal, Vol. 12, Núm. 3, pp. 420-426

  4. Influence of calcium concentration in haemodialysis fluid on blood pressure control

    Nefrologia, Vol. 39, Núm. 1, pp. 44-49

  5. High convective volumes are associated with improvement in metabolic profile in diabetic patients on online haemodiafiltration

    Nefrologia, Vol. 39, Núm. 2, pp. 168-176

  6. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 2, pp. 128-139

  7. An old disease, a new diagnosis; A 49 year-old man with nephrotic syndrome

    Journal of Nephropathology, Vol. 8, Núm. 3

2018

  1. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study)

    Cardiovascular Drugs and Therapy, Vol. 32, Núm. 3, pp. 255-263